Spotlight on crizotinib in the first-line treatment of ALK-positive advanced non-small-cell lung cancer: patients selection and perspectives

Lignende værker

• Crizotinib as first line therapy for advanced ALK-positive non-small cell lung cancers
  af: Chuang, Jody C., et al.
  Udgivet: (2015)
• Fatal Haemoptysis Associated with Dramatic Response to Crizotinib in an ALK-Rearranged Lung Adenocarcinoma
  af: Mussat, Elodie, et al.
  Udgivet: (2016)
• Alectinib can replace crizotinib as standard first-line therapy for ALK-positive lung cancer
  af: Uemura, Takehiro, et al.
  Udgivet: (2017)
• Is there a progression‐free survival benefit of first‐line crizotinib versus standard chemotherapy and second‐line crizotinib in ALK‐positive advanced lung adenocarcinoma? A retrospective study of Chinese patients
  af: Cui, Shaohua, et al.
  Udgivet: (2016)
• Moving molecularly directed therapies to the first-line in ALK-positive lung cancer: crizotinib is just the beginning
  af: Klempner, Samuel J., et al.
  Udgivet: (2015)